Edaravone Mitsubishi-Tokyo
Tabrizchi, R.
Current Opinion in Investigational Drugs 1(3): 347-354
2000
ISSN/ISBN: 1472-4472 PMID: 11249718 Document Number: 515653
Mitsubishi-Tokyo (formerly Mitsubishi Chemical) is developing edaravone (norphenazone), a free radical scavenger, for the potential treatment of cardiovascular disease, cerebrovascular ischemia and cerebral edema. By February 2000, edaravone had been filed in Japan for the treatment of acute brain infarction, and was in phase III trials for subarachnoid hemorrhage [365460]. The compound blocks the action of the lipoperoxide, 15-HPETE, which normally increases with age and may be associated with neurodegeneration.